Risk Analysis and Measures of Fetal Skeletal Abnormalities Caused by Magnesium Sulfate Injection

Abstract

Abstract: According to the situation of magnesium sulfate injection risk control measures at home and abroad, the background and basis of its safety warnings are further analyzed so as to explore the correlation between magnesium sulfate injection and fetal skeletal abnormalities. The newly exposed risk and the magnesium sulfate injection, which leads to change the balance of risk/benefit, need each side to give more attention and take corresponding measures.

Key words: magnesium sulfate injection, fetus, skeletal abnormalities, risk management

CLC Number:

R971.6

WANG Chun-ting, ZHENG Ming-jie. Risk Analysis and Measures of Fetal Skeletal Abnormalities Caused by Magnesium Sulfate Injection[J]. Chinese Journal of Pharmacovigilance, 2014, 11(7): 429-431.

References

[1] Yokyama K, Takahashi N, Yada Y. Prolonged maternal magnesium administration and bone metabolism in neonates[J]. Early Hum Dev, 2010,86(3):187-191.
[2] Wedig K E, Kogan J, Schorry E K, et al. Skeletal demineralization and fractures caused by fetal magnesium toxicity[J]. J Perinatol, 2006,26(3):371-374.
[3] Malaeb S N, Rassi A, Haddad M C. Bone mineralization in newborns whose mothers received magnesium sulphate for tocolysis of premature labor[J].PediatrRadiol, 2004,34(5):384-386.
[4] Kaplan W, Haymond M W, Mckay S, et al. Osteopenic effects of magnesium sulfate in multiple pregnancies[J].Pediatric Endocrinol-ogy and Metabolism, 2006,19(10):1225-1230.
[5] Schanler R J, Smith G, Burns P A. Effects of long-term maternal intravenous magnesium sulfate therapy on neonatal calcium metabolism and bone mineral content[J]. GynecolObstetInvest,1997,43(4):236-241.
[6] Nassar A H, Sakhei K, Maarouf H, et al. Adverse maternal and neonatal outcome of prolonged course of magnesium sulfate tocolysis[J].ActaObstetGynecol Scan, 2006,85(9):1099-1103.
[7] Matsuda Y, Maeda Y, Ito M, et al. Effect of magnesium sulfate treatment on neonatal bone abnormalities[J]. GynecolObstetInvest,1997,44(2):82-88.
[8] 肖凯,江慧星. 利托君与硫酸镁联用防治早产致不良反应1例[J]. 中南药学,2010,8（10）：798-799.
[9] 彭皓月,彭晨月. 盐酸利托君联合保胎灵胶囊治疗先兆早产的疗效观察及用药安全性分析[J].中国社区医师,医学专业2012,14,(331)：127-128.
[10] 张华. 静脉滴注硫酸镁致过敏反应 1 例[J]. 中国实用医药,2012,
7(24)：199-200.
[11] 秦红霞. 硫酸镁注射液联合小剂量阿司匹林治疗42例妊娠高血压的临床研究[J]. 中国医药指南,2012,18(10):562-563.
[12] 韩健. 硫酸镁注射液治疗支气管哮喘的疗效观察[J].临床合理用药,2009,2(18):41.
[13] 曹忠志,朱小.硫酸镁在临床应用中的问题[J].医药产业资讯,2006,3(8):64-65.
[14] 谢惠民,周再丽.药源性猝死与药源性中毒和误用[J].中国医刊,2002,37(6):53-54.
[15] 王穗琼,林建昌,陈小葵.抗早产药的临床应用与分析[J].中国药房, 2007,18(29):2258-2259.
[16] 叶萍,赵望华,余雪燕.早产儿硫酸镁中毒1例报告[J].新生儿科杂志,2002,17(4):160.
[17] 刘芬,丁依玲.早产的药物治疗[J].中国医刊, 2007,42(12):63-65.
[18] 蔡文卫.静脉滴注硫酸镁致血压急剧下降1例[J].淮海医药,2013,1（1）：1008.